Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Depot in Type 2 Diabetes Mellitus
NCT07563699Phase 2Recruiting
- Sponsor
- Mapi Pharma
- Start
- Aug 2026
- Primary completion
- May 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Mapi Pharma. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07563699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563699.